BIZENGRI

(Zenocutuzumab)

Phase 2Monoclonal antibody

MMerus B.V.

BIZENGRI is one of 17 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

Adenocard

Astellas

Preclinical

1 4

BIZENGRI

MMerus B.V.

Phase 2

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Acupan

YYonsei University

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Patients With Solid Tumors

NCT02912949

Clinical

Trials by Indication[1]

Breast Cancer1 trial

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Completed·MMerus B.V.·Phase 2·NCT03321981·105 enrolled

Patients With Solid Tumors1 trial

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Active, not recruiting·PPartner Therapeutics, Inc.·Phase 2·NCT02912949·250 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 4, 2024

BIZENGRI

BLA BLA761352

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Zenocutuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zenocutuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zenocutuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761352). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Merus B.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: MMerus B.V.

BIZENGRI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer1 trial

Patients With Solid Tumors1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News